Table 1 Main clinical characteristics and results for the whole patients population and according to LDH pre-treatment values (above or below the cut-off) and to the LDH variation pre- and post-treatment.
Characteristics | Whole Group | pre-treatment LDH | pre-/post-treatment LDH variation | ||||
|---|---|---|---|---|---|---|---|
Group A | Group B | p value | LDH | LDH | p value | ||
LDH < cutoff | LDH ≥ cutoff | decreased | increased | ||||
n = 114 | n = 56 | n = 58 | n = 38 | n = 76 | |||
Age (range) | 68 (31–84) | 67 (43–79) | 69 (31–84) | 67 (43–84) | 68 (31–82) | ||
Gender (%) | |||||||
Males | 50 (44) | 30 (54) | 20 (34) | ns | 13 (34) | 37 (49) | ns |
Females | 64 (56) | 26 (46) | 38 (66) | 25 (66) | 39 (51) | ||
ECOG PS (%) | |||||||
0–1 | 78 (68) | 43 (77) | 35 (60) | ns | 29 (76) | 49 (64) | ns |
≥2 | 36 (32) | 13 (23) | 23 (40) | 9 (24) | 27 (36) | ||
Primitive tumour site (%) | |||||||
Gallbladder tumours | 25 (22) | 11 (20) | 14 (24) | 8 (21) | 17 (22) | ||
Extrahepatic distal cholangiocarcinoma | 17 (15) | 7 (12) | 10 (17) | ns | 6 (16) | 11 (15) | ns |
Extrahepatic hilar cholangiocarcinoma | 11 (10) | 8 (14) | 3 (5) | 4 (10) | 7 (9) | ||
Intrahepatic cholangiocarcinoma | 61 (53) | 30 (54) | 31 (54) | 20 (53) | 41 (54) | ||
Previous surgery | |||||||
Yes | 49 (43) | 25 (45) | 24 (41) | ns | 17 (45) | 32 (42) | ns |
Not | 65 (57) | 31 (55) | 34 (59) | 21 (55) | 44 (58) | ||
Ca19.9 serum levels | |||||||
≤upper normal rate | 49 (43) | 27 (48) | 22 (38) | ns | 19 (50) | 30 (39) | ns |
>upper normal rate | 65 (57) | 29 (52) | 36 (62) | 19 (50) | 46 (61) | ||
Objective response (%) | |||||||
Disease Control (SD + PR) | 65 (57) | 40 (71) | 25 (43) | 0.002 | 31 (82) | 34 (45) | 0.0001 |
Not response (PD) | 49 (43) | 16 (29) | 33 (57) | 7 (18) | 42 (55) | ||
Survival | |||||||
mPFS (months) | 3.4 | 5.0 | 2.6 | 0.0042 | 6.2 | 3.0 | 0.0009 |
mOS (months) | 6.8 | 7.7 | 5.6 | 0.324 | 12.1 | 5.1 | <0.0001 |
